Clinical Trials Logo

Trisomy 8 clinical trials

View clinical trials related to Trisomy 8.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01584531 Completed - Clinical trials for Myelodysplastic Syndrome

Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome

ONTARGET
Start date: May 2012
Phase: Phase 2
Study type: Interventional

The primary objectives of this study are to determine if rigosertib sodium, given orally in the form of soft gel capsules, is safe and is associated with a reduction in the number of blood transfusion units that are needed in patients with myelodysplastic syndrome (MDS) classified as Low or Intermediate-1 (Int-1) (any cytogenetics) or trisomy 8 Intermediate 2 (Int-2) in the International Prognostic Scoring System (IPSS) who are transfusion-dependent. Rigosertib will be taken on days 1 to 21 of a 21-day cycle.